AP2, which recognizes a complex-dependent epitope on GPIIb-IIIa, was provided by Dr Robert R. immunoglobulin G (IgG) were injected intraperitoneally 30 minutes before introduction of HPA-1a antibodies. Blood samples were taken periodically and analyzed by circulation cytometry to determine the percentage of circulating human PLTs. == Results == Anti-HPA-1a IgG from NAIT cases were able to efficiently obvious HPA-1apositive PLTs from murine blood circulation. Administration of SZ21 F(ab)2fragments not only inhibited binding of HPA-1a antibodies to circulating human PLTs, preventing their clearance, but also displaced bound HPA-1a antibodies from your PLT surface. == Conclusion == F(ab)2fragments of HPA-1aselective MoAb SZ21 effectively inhibit anti-HPA-1amediated clearance of human PLT circulating in an in vivo NOD/SCID mouse model. These results suggest that brokers that inhibit binding of anti-HPA-1a to PLTs may have therapeutic potential in the treatment of NAIT. Neonatal alloimmune thrombocytopenia (NAIT) results from maternal alloimmunization to paternally inherited human platelet-specific alloantigens (HPA) expressed on the surface of fetal platelets (PLTs)1. The transplacental passage of maternal HPA-1a antibodies prospects to destruction of fetal PLTs. Of the 16 alloantigen systems recognized to date, HPA-1a antibodies are the most frequent cause of severe thrombocytopenia in Caucasian persons2,3. A single Leu33Pro amino acid GT 949 polymorphism is responsible for the HPA-1a alloimmunization4. The GT 949 manifestations of NAIT range from subclinical thrombocytopenia to intracranial hemorrhage, the latter of which occurs in 10 to 20 percent of the NAIT cases1. Although most intracranial hemorrhage cases are reported to occur EMCN in utero, NAIT-affected newborns are also at risk to develop cerebral hemorrhage, especially in the first 24 to 48 hours postpartum1. Owing to the absence of a routine screening program to predict maternal HPA alloimmunization, first-pregnancy NAIT cases are usually recognized postnatally. These cases require immediate management of severe thrombocytopenia to achieve a rapid correction of GT 949 PLT count to prevent intracranial hemorrhage in the neonates. Currently, HPA-1anegative PLT transfusion is the treatment of choice1. Because only 2.5 percent of Caucasian persons are HPA-1bb, the availability of HPA-1anegative PLTs is restricted to major transfusion centers3. Other therapeutic options such as high-dose intravenous globulin and random PLT transfusion have some limitations, like delay of action and refractoriness1,5,6. Therefore, there is a need for novel therapeutic methods that might efficiently prevent clearance of newborn PLTs. SZ21, a monoclonal antibody (MoAb) directed against PLT glycoprotein (GP) IIIa, binds at or near the HPA-1a epitope7-9. Recently, we developed an in vivo model system in which human PLTs are injected into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and allowed to circulate for up to 24 hours10. By using this model, it is possible to investigate the fate of human PLTs in the presence of PLT-reactive antibodies and to examine the potential for novel therapeutics to prevent PLT clearance. In this study, we show that coinjection of divalent F(ab)2fragments of SZ21 prevents anti-HPA-1a mediated human PLT clearance from your circulation. == Materials and Methods == == Antibodies == Immunoglobulin G (IgG) fractions were isolated from three different anti-HPA-1a serum samples implicated in NAIT cases using an IgG purification gel as explained by the manufacturer (Pierce, Rockford, IL). F(ab)2fragments of SZ21 (Beckman Coulter, Fullerton, CA) were prepared using a F(ab)2preparation kit (Pierce). The purity and the binding capacity of the IgG and F(ab)2preparation were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and circulation cytometry. Isotype-matched F(ab)2was obtained from Jackson Immuno-Research Laboratories, Inc. (West Grove, PA). AP2, which recognizes a complex-dependent epitope on GPIIb-IIIa, was provided by Dr Robert R. Montgomery (Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI)11. == Antibody binding studies == Whole blood was drawn from HPA-1ab or HPA-1bb donors into acid-citrate-dextrose (ACD), supplemented with 50 ng per mL prostaglandin E1(PGE1) and centrifuged at 200 gfor 10 minutes. PLT-rich plasma was collected and supplemented with GT 949 50 ng per mL PGE1and centrifuged at 700 gfor 10 minutes. The PLT pellet was resuspended with altered Tyrodes-HEPES (Tyrode-N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid) buffer (10 mmol/L HEPES [pH 7.4], 12 mol/L NaHCO3, 137 mol/L NaCl, 2.7 mol/L KCl, 5 mol/L glucose, 0.25% bovine serum albumin), and the PLT concentration was adjusted to 2.0 108per mL. Fifty microliters of PLT suspension from both allotypes was incubated with the indicated concentrations of SZ21 F(ab)2. Binding of SZ21 F(ab)2was detected using anti-mouse F(ab) (goat anti-mouse F(ab), 1:250, Jackson ImmunoResearch Laboratories, Inc.). In experiments designed to examine the ability of SZ21 F(ab)2to block anti-HPA-1a binding, PLTs were obtained from an HPA-1ab, blood group O donor and incubated with SZ21 F(ab)2fragments at concentrations ranging.